Charles River kept at hold by Jefferies

Jefferies & Co., Inc. analyst David Windley maintained Charles River Laboratories International Inc. at hold and a $42, 12-month price target. For the second quarter, the company reported non-GAAP earnings per share of $0.57, above Jefferies' $0.50 estimate and consensus of $0.53. Net revenues of $267.9 million also beat the analyst's estimate of $265.7 million and consensus of $263 million. Charles River management reiterated its 2006 non-GAAP guidance of $2.12 to $2.18, with sales growth between 6% and 8%. Shares of the Wilmington, Mass.-based pharmaceutical products company were up 26 cents, or 0.69%, at $38.03, on volume of 807,300 shares versus the three-month running average of 1,063,960 shares. (NYSE: CRL)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.